Trametinib is FDA-approved for the treatment of human patients with unresectable or metastatic melanoma harboring BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E or V600K mutations (18). Here, BRAF is linked to metastatic melanoma.